Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...

The Australian patent represents the first patent granted for the Company's new point-of-care testing platformSALT LAKE CITY, ...

Out of the 386 regencies and mayoralties targeted by the Health Ministry, fewer than half are estimated to have public health ...

IPOs don’t always get the attention they deserve, yet they play a vital role in renewing the stock market. They bring new ...

DNA testing charges in Kenya vary primarily based on whether you are seeking a government service or a private facility.

Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the ...

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

Co-Diagnostics ( ($CODX) ) just unveiled an update. On December 5, 2025, Co-Diagnostics’ stockholders approved a reverse stock split ...

CRISPR biosensors enable real-time health monitoring with attomolar sensitivity, wearable integration, and multiplex diagnostics for faster, personalized care.

A new, highly accurate testing service that improves the early-stage detection of bowel cancer with strong clinical validity will be available in the UK within the next few weeks. The service ...